Application of the Clinical Outcomes, Healthcare Resource Utilization, and Related Costs Model in Chronic Obstructive Pulmonary Disease Patients.

IF 3.5 3区 医学 Q2 RESPIRATORY SYSTEM
Respiration Pub Date : 2024-10-09 DOI:10.1159/000541406
Carlos J Alvarez-Martinez, Jorge Vélez, Clara Goñi, Joaquín Sánchez-Covisa, Mónica Juárez-Campo, Luciano Escudero, José L Bernal, Nicolás Rosillo, Miguel Hernández, Héctor Bueno
{"title":"Application of the Clinical Outcomes, Healthcare Resource Utilization, and Related Costs Model in Chronic Obstructive Pulmonary Disease Patients.","authors":"Carlos J Alvarez-Martinez, Jorge Vélez, Clara Goñi, Joaquín Sánchez-Covisa, Mónica Juárez-Campo, Luciano Escudero, José L Bernal, Nicolás Rosillo, Miguel Hernández, Héctor Bueno","doi":"10.1159/000541406","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The change in prevalence and management of chronic obstructive pulmonary disease (COPD) led to changes in outcomes and costs. We aimed to assess current clinical outcomes, resource utilisation, and costs in COPD.</p><p><strong>Methods: </strong>Retrospective, observational study of a cohort of consecutive COPD patients who visited the emergency department (ED) of a large tertiary hospital in 2018. The study measured baseline characteristics, 30-day and 1-year mortality, readmission, re-ED visit rates, and costs using the Clinical Outcomes, HEalthcare REsource utilisatioN, and relaTed costs (COHERENT) model, validated for heart failure. This model, featuring a colour graphic system, tracks time spent in different clinical situations (home, ED, hospital), considering vital status, healthcare resource use, and related costs.</p><p><strong>Results: </strong>In 2018, 2,384 patients with a primary COPD diagnosis visited the ED. The average age was 76 years, with 40% women. Observed mortality rates were 7.6% in-hospital, 8.5% at 30 days, and 23.4% at 1 year. The readmission rates were 9.9% and 36.1%, respectively. The cohort's 1-year cost was approximately EUR 14.6 million (USD 15.95 million), with a median cost per patient of EUR 3,298 (USD 3,603.96). Hospitalisation incurred the highest costs, with initial hospitalisation and readmissions accounting for 44.7% and 42.6% of expenditures, respectively.</p><p><strong>Conclusion: </strong>One-year mortality and readmission rates for patients with COPD visiting the ED remain high with a significant economic impact on the health system. This burden justifies special programs to improve their care.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiration","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541406","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The change in prevalence and management of chronic obstructive pulmonary disease (COPD) led to changes in outcomes and costs. We aimed to assess current clinical outcomes, resource utilisation, and costs in COPD.

Methods: Retrospective, observational study of a cohort of consecutive COPD patients who visited the emergency department (ED) of a large tertiary hospital in 2018. The study measured baseline characteristics, 30-day and 1-year mortality, readmission, re-ED visit rates, and costs using the Clinical Outcomes, HEalthcare REsource utilisatioN, and relaTed costs (COHERENT) model, validated for heart failure. This model, featuring a colour graphic system, tracks time spent in different clinical situations (home, ED, hospital), considering vital status, healthcare resource use, and related costs.

Results: In 2018, 2,384 patients with a primary COPD diagnosis visited the ED. The average age was 76 years, with 40% women. Observed mortality rates were 7.6% in-hospital, 8.5% at 30 days, and 23.4% at 1 year. The readmission rates were 9.9% and 36.1%, respectively. The cohort's 1-year cost was approximately EUR 14.6 million (USD 15.95 million), with a median cost per patient of EUR 3,298 (USD 3,603.96). Hospitalisation incurred the highest costs, with initial hospitalisation and readmissions accounting for 44.7% and 42.6% of expenditures, respectively.

Conclusion: One-year mortality and readmission rates for patients with COPD visiting the ED remain high with a significant economic impact on the health system. This burden justifies special programs to improve their care.

在慢性阻塞性肺病患者中应用临床结果、医疗资源利用率和相关成本(COHERENT)模型。
导言:慢性阻塞性肺病(COPD)发病率和管理的变化导致了治疗效果和成本的变化。我们旨在评估慢性阻塞性肺病目前的临床结果、资源利用率和成本:对 2018 年在一家大型三甲医院急诊科(ED)就诊的连续 COPD 患者队列进行回顾性观察研究。该研究使用针对心力衰竭验证过的临床结果、医疗资源利用和相关成本(COHERENT)模型,测量了基线特征、30 天和 1 年死亡率、再入院率、再次急诊就诊率和成本。该模型采用彩色图形系统,可追踪患者在不同临床情况下(家庭、急诊室、医院)所花费的时间,同时考虑生命体征状况、医疗资源使用情况和相关成本:2018 年,2384 名主要诊断为慢性阻塞性肺病的患者到急诊室就诊。平均年龄为 76 岁,女性占 40%。观察到的院内死亡率为 7.6%,30 天内死亡率为 8.5%,一年内死亡率为 23.4%。再入院率分别为 9.9% 和 36.1%。组群一年的费用约为 1460 万欧元(1595 万美元),每位患者的费用中位数为 3298 欧元(3603.96 美元)。住院产生的费用最高,首次住院和再次入院分别占支出的44.7%和42.6%:结论:到急诊室就诊的慢性阻塞性肺病患者的一年死亡率和再入院率居高不下,对医疗系统造成了巨大的经济影响。这种负担证明有必要制定专门的计划来改善对他们的护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Respiration
Respiration 医学-呼吸系统
CiteScore
7.30
自引率
5.40%
发文量
82
审稿时长
4-8 weeks
期刊介绍: ''Respiration'' brings together the results of both clinical and experimental investigations on all aspects of the respiratory system in health and disease. Clinical improvements in the diagnosis and treatment of chest and lung diseases are covered, as are the latest findings in physiology, biochemistry, pathology, immunology and pharmacology. The journal includes classic features such as editorials that accompany original articles in clinical and basic science research, reviews and letters to the editor. Further sections are: Technical Notes, The Eye Catcher, What’s Your Diagnosis?, The Opinion Corner, New Drugs in Respiratory Medicine, New Insights from Clinical Practice and Guidelines. ''Respiration'' is the official journal of the Swiss Society for Pneumology (SGP) and also home to the European Association for Bronchology and Interventional Pulmonology (EABIP), which occupies a dedicated section on Interventional Pulmonology in the journal. This modern mix of different features and a stringent peer-review process by a dedicated editorial board make ''Respiration'' a complete guide to progress in thoracic medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信